Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units

Study Overview
=================
Brief Summary
-----------------
The actual COVID-19 epidemy is an unprecedented healthcare problem. Although acute respiratory distress syndrome is the main organ failure, acute kidney injury (AKI) has appeared to be more frequent and more severe than expected. Some data suggested a potential direct renal tropism of the virus, or undirect injury by cytokine storm. The aims of this study are: To describe incidence, severity and mortality associated with AKI during covid-19 infection in ICU To identify specific risk factors for AKI To explore pathophysiologic mechanism of AKI during COVID-19 infection

Official Title
-----------------
Acute Kidney Injury and Renal Outcomes for COVID-19 Patients in Intensive Care Units

Conditions
-----------------
on Occurrence of Acurate Kidney Injury During Intensive Care Unit, Abnormalities of Urinary Analysis

Intervention / Treatment
-----------------
* Other: Non interventional study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed COVID-19 infection (by qRT-PCR and/or TDM typical lesion) Needing intensive care Exclusion Criteria: End Stage Renal Disease patients (with pre-existent dialysis) Intensive care support for less than 72h (transfer in conventional unit or death)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AKI (-)<br>patients treated in ICU for COVID-19 infection and without occurrence of AKI (define as creatinine > 1,5x baseline according with KDIGO guidelines) | |
| AKI (+)<br>patient treated in ICU for COVID-19 infection and with occurrence of AKI among which: • Severe AKI patients (define as creatinine > 3x baseline or need for renal replacement therapy according with KDIGO guidelines) who will participate to biocollection and to post-mortem biopsy (if death). | Other: Non interventional study<br>* Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient. Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary endpoint is the incidence, the severity and the mortality associated with AKI during COVID-19 severe infection | AKI will be defined according with KDIGO guidelines: increase in creatinine of more than 1,5 fold compared to baseline Severe CVOID-19 infection is defined as 1/ confirm COVID-19 infection (by TDM and/or qRT-PCR) 2/ Requirement of ICU support during more than 72h | 7 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acurate Kidney Injury